Blood baseline neutrophil count predicts bevacizumab efficacy in glioblastoma

Bevacizumab is used to treat glioblastoma; however, no current biomarker predicts its efficacy. We used an exploratory cohort of patients treated with the radiochemotherapy then bevacizumab or chemotherapy at recurrence (N = 265). Bevacizumab use increased median overall survival (OS) 18.7 vs 11.3 m...

Descripción completa

Detalles Bibliográficos
Autores principales: Bertaut, Aurélie, Truntzer, Caroline, Madkouri, Rachid, Kaderbhai, Coureche Guillaume, Derangère, Valentin, Vincent, Julie, Chauffert, Bruno, Aubriot-Lorton, Marie Hélene, Farah, Wahlid, Mourier, Klaus Luc, Boidot, Romain, Ghiringhelli, Francois
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342600/
https://www.ncbi.nlm.nih.gov/pubmed/27487142
http://dx.doi.org/10.18632/oncotarget.10898

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342600/
https://www.ncbi.nlm.nih.gov/pubmed/27487142
http://dx.doi.org/10.18632/oncotarget.10898

Ejemplares similares